This is an era for DPP4-inhibitors, which are currently No.1 prescribed oral hypoglycemic agents (OHA) over the world. In Korea, there have been launched more than 5 different DPP4 inhibitors and their effects on glycemic control seemed to be very similar. Teneligliptin, recently launched in Korea, we need to understand what make Teneligliptin different from other DPP4 inhibitors. In this lecture, I want to compare the result of Teneligliptin clinical data in comparison with other clinical trials using well-known DPP4 inhibitors. Especially, I want to focus on its effects of glycemic variability and unique safety profiles.